Relmada Therapeutics, Inc.
RLMD- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001553643
In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Relmada Therapeutics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 91
- −19 vs. Q4 2022
- Shares held
- 17.8M
- −1.35M (−7.1%) vs. Q4 2022
- Total value
- $40.3M
- −$26.5M (−39.7%) vs. Q4 2022
- New holders
- 10
- 26 more added
- Sold out
- 29
- 33 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RLMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 126 | $693.7M |
| Q1 2026 | 103 | $588.8M |
| Q4 2025 | 78 | $245.8M |
| Q3 2025 | 44 | $15.5M |
| Q2 2025 | 50 | $3.18M |
| Q1 2025 | 44 | $1.68M |
| Q4 2024 | 48 | $4.36M |
| Q3 2024 | 69 | $40.2M |
| Q2 2024 | 79 | $40.7M |
| Q1 2024 | 93 | $66.5M |
| Q4 2023 | 83 | $56.4M |
| Q3 2023 | 88 | $45.0M |
| Q2 2023 | 95 | $39.7M |
| Q1 2023 | 91 | $40.3M |
| Q4 2022 | 110 | $66.8M |
| Q3 2022 | 134 | $953.6M |
| Q2 2022 | 113 | $468.5M |
| Q1 2022 | 113 | $623.1M |
| Q4 2021 | 97 | $467.2M |
| Q3 2021 | 87 | $262.8M |
| Q2 2021 | 85 | $318.3M |
| Q1 2021 | 82 | $335.7M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Relmada Therapeutics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −45,424−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −35,281−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −26,299−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −26,258−100.0% | Sold out |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −22,233−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −21,420−100.0% | Sold out |
| Chicago Partners Investment Group LLC | 0 | $0 | 0.00% | −14,310−100.0% | Sold out |
| Quantamental Technologies LLC | 0 | $0 | 0.00% | −15,674−100.0% | Sold out |
| Point72 Middle East FZE | 0 | $0 | 0.00% | −15,517−100.0% | Sold out |
| Axq Capital, LP | 0 | $0 | 0.00% | −12,483−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −12,334−100.0% | Sold out |
| Exchange Traded Concepts, LLC | 0 | $0 | 0.00% | −11,981−100.0% | Sold out |
| TCI Wealth Advisors, Inc. | 0 | $0 | 0.00% | −1,077−100.0% | Sold out |
| Red Tortoise LLC | 0 | $0 | 0.00% | −465−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −185−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Byrne Asset Management LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −27−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −2−100.0% | Sold out |